Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311915 | 0.84 | BACE1 (0.39) | KDM4EMAPTLMNABACE1ALOX5 | |
| SCHEMBL6314069 | 0.83 | CACNA1C (0.38) | KDM4EMEN1KMT2AMAPTLMNA | |
| SCHEMBL6313190 | 0.81 | MAPT (0.39) | KDM4EMEN1KMT2AMAPTLMNA | |
| SCHEMBL6138540 | 0.80 | CACNA1F (0.41) | KDM4EMAPTLMNAALDH1A1HPGD | |
| SCHEMBL6137169 | 0.80 | ALDH1A1 (0.46) | KDM4EMEN1KMT2AMAPTLMNA | |
| SCHEMBL6311828 | 0.80 | ALDH1A1 (0.45) | KDM4EMEN1KMT2AMAPTLMNA | |
| SCHEMBL6312858 | 0.79 | ALDH1A1 (0.40) | KDM4EMEN1KMT2AMAPTLMNA | |
| SCHEMBL6137371 | 0.79 | ALDH1A1 (0.40) | KDM4EMAPTLMNAHSD17B10ALDH1A1 | |
| SCHEMBL6137120 | 0.79 | CACNA1F (0.44) | KDM4EMAPTLMNATSHRALDH1A1 | |
| SCHEMBL6137084 | 0.79 | MAPT (0.45) | KDM4EMEN1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900214-B2 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | claimed |
| EP-1373223-A4 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1373223-A1 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2002079169-A1 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | claimed |
| US-20020143026-A1 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | claimed |
| US-6900214-B2 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SINGNAL PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| EP-1373223-A4 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1373223-A1 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002079169-A1 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020143026-A1 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143026-A1 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | CCNB1, BUB1B, BUB1 | KDM4E 1638/4885MEN1 1168/4885KMT2A 1829/4885 |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | KDM4E 3349/4885MEN1 4284/4885KMT2A 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.